appear unrelated to Lewy body metabolism, the ques-
tion of whether neurodegeneration proceeds through cultured neurons or brain sections from flies expressing Pael-R or ␣-synuclein alone, or in combination with hualtered Lewy body metabolism or through an independent pathway remains unresolved. Finally, most of the man parkin. Results from these studies revealed a reduction in the abundance of Pael-R in many (but not all) previously identified parkin binding components appear to be substrates of parkin rather than parkin cofactors, neurons coexpressing parkin and Pael-R after 6 days in culture with respect to age-matched control neurons and thus, little is currently known of the pathways in which parkin normally acts. Three recently published expressing only Pael-R, or neurons coexpressing Pael-R and parkin at earlier time points. Identical results were papers have begun to address these issues by demonstrating a role for parkin in protecting neurons from observed in dopaminergic neurons, suggesting that parkin attenuates Pael-R toxicity by mediating the degradadiverse insults: ␣-synuclein toxicity, proteasomal inhibition, Pael-R accumulation, and kainate-induced excitotion of this protein. The finding that parkin and Pael-R largely colocalize suggests that parkin is directly intoxicity.
To investigate the toxicity of Pael-R to dopaminergic volved in Pael-R degradation. By contrast, the overall abundance of ␣-synuclein appeared to be unaffected vation suggests that parkin acts specifically on aberrant ␣-synuclein deposits. Pael-R-mediated dopaminergic neuron loss was attenuated by coexpression of human parkin and exacerbated These studies are important because they provide the first evidence that Pael-R is selectively toxic to dopaminby inhibiting the activity of endogeneous fly parkin using RNA interference (RNAi). Importantly, RNAi-mediated ergic neurons and that this toxicity, as well as ␣-synuclein-mediated toxicity, is influenced by parkin. The findpartial inactivation of Drosophila parkin was found to have no effect on dopaminergic neuron survival in the ing that parkin is able to mitigate ␣-synuclein toxicity is of particular significance because this observation absence of Pael-R, suggesting that the cell loss mediated by RNAi results from enhanced Pael-R toxicity. In concert, these three recent papers expand the potential role of parkin to guard against Pael-R and F-box/WD proteins. The authors further demonstrated that hSel-10 was associated with parkin in brain homog-␣-synuclein toxicity, proteasome dysfunction, and excitotoxic cell death. Intriguingly, parkin and each of these enates and used the E2 UbcH7 to potentiate parkin ubiquitin ligase activity. Cyclin E is a known substrate diverse insults have previously been implicated in the pathogenesis of dopaminergic neuronal death in Parkinof the SCF hSel-10 complex, and cyclin E was also recruited to the parkin-Cul1 complex and ubiquitinated. Inhibition son's disease. In addition, the current studies identify a novel parkin substrate, cyclin E. Key areas for future of parkin using RNAi increased levels of cyclin E, consistent with a role for parkin in cyclin E degradation. work include demonstration that emerging parkin substrates like cyclin E indeed play a critical role in dopaminThe identification of cyclin E as a parkin substrate is intriguing because cyclin E, with its partner cyclinergic neurodegeneration in vivo. Defining a role for endogenous parkin, as opposed to overexpressed parkin, dependent kinase 2, is a key regulator of the G1/S transition during the cell cycle. Inappropriate activity of cell in protecting dopaminergic neurons from ␣-synuclein toxicity will also be important. The mechanisms by which cycle-related kinases, perhaps through activation of the cell cycle, has been suggested as an important mediator parkin protects from diverse toxic insults remains to be determined, but two recent papers suggest a final of death in postmitotic neurons exposed to excitotoxins like kainate (Copani et al., 2001) . Thus, Staropoli et al.
common pathway of parkin toxicity in vivo involving mitochondrial swelling, cytochrome c release, and apoassayed the ability of parkin overexpression to protect from kainate-induced cell death. Overexpression of parptotic cell death (Figure 1 ). In the first study, overexpression of parkin protected PC12 cells from cell death medikin rescued cultured cerebellar granular cells and midbrain dopaminergic neurons from kainate-induced cell ated by ceramide (Darios et al., 2003) . In these PC12 cells, parkin acted by delaying mitochondrial swelling death. Parkin-mediated protection correlated with decreased cyclin E accumulation. Conversely, reducing and cytochrome c release. Parkin copurified with mitochondria in PC12 cells and was localized on the outer parkin levels with RNAi sensitized cerebellar granular cells and midbrain dopaminergic neurons to kainate toxmitochondrial membrane. Similarly, Drosophila completely lacking parkin exhibited adult-onset muscle deicity. Interestingly, reducing parkin levels had no influence on MPPϩ toxicity, suggesting that pathways medigeneration characterized by mitochondrial swelling and subsequent apoptosis of myocytes (Greene et al., 2003) . ating dopaminergic toxicity of the two compounds were distinct. Cyclin E levels were also not elevated in culMale parkin mutant flies were also sterile. Analysis of the male germline revealed pronounced pathology of tured neurons treated with MPPϩ, further suggesting that pathways of toxicity were distinct. However, MPPϩ the mitochondrial derivatives that form the sperm tail, suggesting that mitochondrial dysfunction is a common had substantially less toxicity than kainate under the 
